- This Forum
- Live Webcast from The San Antonio Breast Cancer Symposium
- Sabcs
- Circulating Tumor Cells
- Another Live Webcast from San Antonio Sunday December 17th
- Basics on San Antonio
- Walter Reed Cancer Vaccine
- Arimidex Plus trastuzumab (Phase III TAnDEM study results)
- Lapatinib Effective for Inflammatory Breast Cancer: Presented at SABCS
- Analysis: Breast-cancer vaccine advancing
- Breast cancer drop tied to hormones
- Roche's Xeloda, Avastin in combination offer cancer patients clinical benefit
- Comparison, ACT + Herceptin, TC + Herceptin
- 2006 Komen Brinker Awards
- Tests predict breast-cancer response
- perspectives
- Hsp90 Inhibitor, Tanespimycin
- Ending Periods Helps Cancer Survival
- SABCS: Anthracycline May Be Superfluous in Breast Cancer Regimens
- Aromasin May Cut Breast Cancer Return
- Pill Fights Deadly Breast Cancer
- Less-toxic remedies gain in battle on breast cancer
- Chemo regimen found inferior
- High Breast Density Puts Women With DCIS at High Risk of Contralateral Invasive Breas
- from San Antonio--new way to evaluate lymph nodes 4 mets with intraoperative results!
- one of the big topics at SABCS:epigenetics producing clinical results>80%responserate
- ***12/24/01 was the launch of...***
- More San Antonio Summaries
- ASCO 2007 Highlights
- Her2 Posters Utilizing VeraTag Assays to be presented at SABCS
- San Antonio Meeting 2007
- San Antonio Meeting 2007
- Abstracts Available on Line
- Her2 Recurrence Rates pre-Herceptin
- The Effects of vaginal estrogens on plasma estradiol levels in women taking AI's
- Increased prevalance of retinal hemorrages among anastrozole users
- Milk Products are a Source of Dietary Progesterone
- Some With Breast Cancer Can Skip Chemo
- SABCS to be renamed
- High Dose Chemo Doesn't Help Breast Cancer
- Triple Negative Breast Cancer
- A Call to scrap Anthracyclines in Breast Cancer
- Naviscan's PEM Flex(TM) Scanner Shows Promise
- Genetic Test predicts when chemo benefit to spread to lymph nodes
- Survival Benefit of Docetaxel Over Doxorubicin in Breast Cancer
- promise in reducing side effects from anastrozole
- New Website for Brain Metastases
- HER2 Vaccine Show Promise in Preliminary Testing
- Stem Cells in Breast Cancer
- Shorter Radiation Breast Cancer treatment
- Comparison of joint problems as reported by patients in a randomised adjuvant trial
- Impact of ERBB2 on prognosis and microarray data
- The clinical significance of polysomy 17 in the HER2+ N9831 intergroup adjuvant trast
- Mechanism of action of herceptin killing of HER-2+ breast cancer cells under in vitro
- Gene testing for b/c in men
- AI's in early breast cancer toxicity and adherence
- Only HER2 Breast Cancer benefits from Adrymycian
- Pregnancy May Dampen Breast Cancer Survival
- Recurrence in Node-Positive Breast Cancer Treated With Tamoxifen
- HER2 Homodimer and HER2 Total Protein Assays
- Change in annual recurrence rates over the last 10 years - NORA study
- Long-term data show superiority of anastrazole over tamoxifen in early breast cancer
- Zometa Offers Three Years of Bone Benefit
- Some Women Get Less Benefit from Tamoxifen
- Genomics Helps Predict Best Treatment
- High Dose Fulvestrant reduces tumor growth
- Progesterone in Dairy Products Poses Risks
- Treatment With Zoledronic Acid Prevents Aromatase Inhibitor-Caused Bone Loss
- Herceptin Helps Women with Multiple Chromosomes Containing HER2 Gene
- Most Doctors' Breast Exams Fail Test
- Male relatives carry risk from breast cancer genes: study
- Amgen Bone Drug Shows Promise
- male breast cancer remains below the radar.
- Drugs Cut Bone Loss of Hormone Therapy
- Benefits of Screening Mammography Extend Past Age 70
- Docetaxel (Taxotere) Outdoes Doxorubicin (Adriamycin)
- Zoledronic Acid Prevents Bone Loss during Endocrine Therapy
- Shorter Adjuvant Radiation Course Found Safe and Effective After Lumpectomy
- High-Dose Chemo Gets Final Nail in Its Coffin
- Aromatase Inhibitor Benefit Continues After End of Treatment
- Stem Cells Used to Fix Breast Defects
- Anastrozole, marketed as Arimidex, produces better results than tamoxifen
- Roche Says Avastin Safe in Trials With Chemotherapy (Update1)
- To Remove or Not to Remove: Scientists Report on Signs That May Guide Lymph Node Deci
- Targeting EGFR in Triple-Negative Breast Cancer
- Ten Years of Tamoxifen May Be Better than Five, but Questions Remain
- Breast Cancer Patients Benefit From Continued Use of Herceptin After Progression
- Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit i
- Herceptin Helps Women With Multiple Chromosomes Containing HER2 Gene, Study Finds
- The TEACH (Tykerb Evaluation After CHemotherapy) trial
- Addition of Xeloda to Herceptin and Docetaxel
- HERmark Presents Assay Results In Metastatic Breast Cancer
- New Drug to Prevent Bone Loss Caused by Breast Cancer Treatment
- Agent Aims at Restoring Hormone-Sensitive Status of Breast Cancer Tumor Cells
- Tykerb shows more brain benefits
- Drug Combination Shrinks Breast Cancer Metastases In Brain
- Five-Year Cutoff on Tamoxifen Adjuvant Therapy Called Off Base Advice
- Importance Of Emotional/educational Needs Among Women With Advanced Breast Cancer
- Further Development of INCB7839 as a New Oral Treatment for Breast Cancer
- IHC versus FISH
- Brazilian team finds Herceptin cost effective
- Several Articles from San Antonio
- BC patients w/1-3 positive nodes and low risk 70-gene profile have excellent survival
- Confirmatory Tissue Biopsy for BC mets strongly recommended
- Multidisciplinary management of menopause symptoms after breast cancer
- For R.B - Her2 and fatty acid synthase in bc cells
- Brenda's Story Featured!
- Multiple Studies Reinforce Clinical Utility of Oncotype
- Gene Test Can Indicate Whether Tamoxifen Can Fight Breast Cancer
- Fat-Derived Stem Cells Used for Breast Reconstruction
- Men Can Also Be Carriers Of Breast Cancer Genes
- Proteomic Blood Test Detects Breast Cancer in Early Trial
- US Oncology Research Network Presents Clinical Studies
- Outcome of HER-2-positive breast cancer tied to hormone receptor status
- Arimidex most effective in breast cancer study
- Tykerb Targets Cancer Stem Cells
- 2008 ASCO Patient Advocate Scholarships Available
- More Advocacy Opportunities at ASCO
- ASCO 2008 - The Group Room
- Avastin shows promise in HER2- breast cancer
- HER2 Survival Rates - We've come a long way
- HER2/HR status & FEC & paclitaxel
- Incidence of Heart Failure from Herceptin does not increase over time
- Drug enhances several therapies
- Early stage BC and Zometa trial results
- Antivascular activity of lapatinib and bevacizumab in primary microcluster cultures
- San Antonio Abstracts on line Early
- A distinct inflammatory marker pattern in patients with AI-induced muculoskeletal sym
- The effect of intermittent versus continuous energy restriction on biomarkers of bc
- Normal breast tissue from bc patients express HER1-4 protein concentrations character
- survival outcomes in HER2 positive breast cancer patients with low grade, nn tumors
- Metastasis-associated microtentacles are induced by Tau
- HER2 homodimer levels correlate w/time to first recurrence in HER2+ bc w/o Herceptin
- Prognostic value of Ki-67 in ER+ grade 2 tumors
- Decreased TGF signaling and increased COX2 expression in dense breasts
- HER-2+ DCIS phenotypes and the transition from in situ to invasive breast cancer
- Using mathematical models to understand the time dependence of the growth of DCIS
- The pattern of metastatic spread among breast cancer sub-types
- Influence of zoledronic acid on disseminated tumor cells (DTC) in primary bc
- Clinical outcomes of patients with T1N0 breast cancers: how important are biological
- Estimating recurrences prevented from using trastuzumab in adjuvant bc in the USA
- Reduction of chemotherapy side effects with a calcium phosphate nanoparticle delivery
- MG28, a novel fatty acid synthase inhibitor, overcomes resistance to anti-HER therapy
- Neratinib (HKI-272), an irreversible pan erbB receptor tyrosine kinase inhibitor
- Determination of HER2 amplification - when should chromosome 17 also be determined
- Lapatinib can activate or supress estrogen receptor (ER) signaling in cell models of
- Intermittent treatment of hormone-dependent breast cancer using exemestane
- Deletion of STAT5 prevents HER2/Neu/ErbB2-induced mammary tumor development
- Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted
- electro-acupuncture for aromatase inhibitor related arthralgia in bc survivors
- Study on survival times for stage IV bc over 3 decades
- Hercetpin tx for recurrence free patients with persistent DTC in bone marrow
- Trastuzumab treatment in elderly patients with advanced breast cancer
- Trastuzumab 6 mg/kg and 4 mg/kg can be infused safely over 30 minutes
- HER2 positive early breast cancers: tumour demographics and trastuzumab therapy
- Combination antiHER therapeutics efficacy of alternative dosing regimens in ER+/HER2
- Evaluation of aromatase expression in mammographically dense and non-dense regions of
- Histologic markers of mammographic breast density: core-needle biopsy tissue from
- Tumor necrosis factor transactivates ErbB2 in breast cancer cells
- Reliable data on 5- and 10-year survival provides accurate estimates of 15-year survi
- BC patients unknowingly dosing themselves with estrogen by using topical moisturizers
- San Antonio Breast Cancer Symposium 2008
- RFA of lumpectomy cavities: technique to increase negative margins
- Complications of methylene blue dye infiltration for sentinel lymph node biopsy in bc
- BCafter stopping estrogen plus progestin in postmenopausal women in the whi
- A novel breast tissue feature strongly associated with risk of breast cancer
- HER-2 expression on circulating tumor cells in metastatic breast cancer
- Behaviour and metastatic potential of Her2+ and Her2-(CETC) during adjuvant therapy
- HER2 Support Group Awards 2 Scholarships
- Metastatic potential of Her2+ and Her2- CETC released during primary systemic chemo
- Abundance and distribution of polychlorinated biphenyls (PCBs) in breast tissue
- Is metabolic syndrome the link between obesity and postmenopausal breast cancer?
- Promoter hypermethylation is an early event in breast carcinogenesis
- The addition of zoledronic acid to neoadjuvant chemotherapy may influence pathologica
- Remarkable complete pathologic response rate in Her2+ stage II/III pts in phase II tr
- HER-2/neu expression/amplification is not stable during tumor progression
- PR receptor levels are associated with time to AI treatment failure
- HER2 amplification does not alter outcome in small (1 cm) tumors
- HER2 amplification predicts breast cancer recurrence but not overall survival
- Low penetrance breast cancer predisposition SNPs are site specific
- Pooled cardiac safety analysis of patients with HER2+ MBC receiving trastuzumab
- San Antonio Abstract on-Significant increased recurrence rates among breast cancer ..
- SABC another abstract on her2+ early stage outcomes...
- Drinking more green tea after reading this abstract
- Musa Meyer's Blog on SABCS
- Breast Cancer Podcasts.
- Presence of an in-situ component is associated with reduced biological aggressiveness
- The coamplification pattern of HER2/NEU amplicon and its clinical significance
- Tumor size vs Her2 amplification in post-meno, ER+ tamoxifen tx pts
- CYP2D6 pharmacogenetics stratifies tamoxifen treatment outcome
- The timing of recurrence after the surgery of breast cancer
- Is there a promotion of metastasis by autologeous breast reconstruction in patients?
- Soreness and sensitivity to sun exposure 10 to 16 years after breast cancer radiother
- Radiofrequency ablation of early breast cancer followed by delayed surgical resection
- Chronobiological rhythms of cytokines level of breast cancer
- Primary endocrine therapy versus chemo in postmen pts w/ ER+ bc: 5 yr results
- Testosterone protection: Salivary hormone levels in newly diagnosed breast cancer pts
- Combined ER and HER-targeted therapy in breast cancer treatment
- Anthracyclines in Early Breast Cancer: Patient Perspectives and Expert Debate
- Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen
- Treatment of node-negative infra-centimetric HER2+ invasive breast carcinomas
- PIK3CA gene expression signature and prognosis within the luminal-B ER+ bc
- Expression profile of CTC and corresponding tumors in primary breast cancer patients
- trastuzumab-related cardiac dysfunction in the HERA Trial with 3.6 years follow- up
- trial of acupuncture for the management of AI associated joint symptoms
- Association between HER2/neu overexpression and calcifications in breast cancer
- Evaluation of Adjuvant! Online to predict the effect of optimal endocrine therapy
- Risk factors associated with trastuzumab-associated cardiac toxicity
- HER-2/neu in tissue and serum at time of primary diagnosis of breast cancer
- Long-term follow-up and factors of survival of HER-2 positive breast cancer patients
- Response to neoadjuvant chemotherapy and outcome based on breast cancer subtype
- Trastuzumab cardiotoxicity: FDA review
- Sensitivity to endocrine therapy of PR+/ER- patients and ER+/PR- patients with HER2+
- Weight gain after adjuvant TAC (docetaxel, doxorubicin, and cyclophosphamide) chemo
- Surgery vs primary endocrine therapy for elderly women
- Off-label drug use in women with breast cancer
- Phase II study of trastuzumab-DM1: Final results
- Pertuzumab monotherapy following trastuzumab-based treatment
- The role of systemic treatment after whole brain radiotherapy (WBRT) in bc patients
- Complications associated with erythropoietin stimulating agents in mbc patients
- Long-term treatment with intravenous bisphosphonates in metastatic breast cancer
- Risk and cost of anthracycline-induced cardiotoxicity among breast cancer patients in
- Data on REOLYSIN® Clinical Trials at ASCO Conference
- Cancer stem cells: consensus at ASCO?
- Article from Orlando
- ASCO: New Drug Class Promising in Breast Cancer
- Cancer Drugs: News from ASCO
- Roche's Herceptin Promises New Use
- Roche Presents Several Abstracts for New Targeted Cancer Drugs at ASCO
- Small molecule inhibitor shows promise in trastuzumab-resistant metastatic breast can
- ASCO: Conflicting Data on Breast Cancer, Tamoxifen, SSRIs
- Phase III Trial Evaluating the Addition of Paclitaxel to Doxorubicin Followed by Cycl
- Oxidative Stress, Obesity, and Breast Cancer Risk: Results From the Shanghai Women's
- Immune-Based Lymphoma Treatment Shows Promise
- Peptide Vaccine
- registHER: Treatment outcomes in patients with HER2+ hormone+ MBC
- Characteristics of subsequent breast cancers in patients with benign breast disease
- Comparison of ER, PR, HER2 in primary and paired metastatic lesions
- Brain metastases in breast cancer: Different survival by biological subtype and Ki67
- What is the evidence for rechallenging with anthracyclines or taxanes in MBC?
- Differential timing and patterns of recurrence among breast cancer subtypes
- ASCO: Micrometastases Signal Need to Treat in Early Breast Cancer
- Breast Cancer Bombshell: Vulcan-Backed BiPar Wows Scientists, Helps Women Live Longer
- Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breas
- Wyeth Donates $100,000 to ASCO Cancer Foundation to Support Cancer Prevention and Car
- Impressive survival data with semimetronomic oral chemo
- Chinese herbal medicine LC07 treating hand-foot syndrome
- Cardiac safety of the lapatinib/letrozole combination
- Concordant HER2 status between malignant CSF cells and primary breast carcinoma tissu
- Multifactorial CNS relapse susceptibility in HER2-positive breast cancer patients